文献速递前列腺癌

雄激素剥夺治疗6个月后的绝对前列腺特异性抗原可预测激素敏感性前列腺癌患者的总体死亡与肿瘤特异性死亡

Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
PubMed 文献 · J Urol · 2022-03-28

该回顾性研究纳入9170例在退伍军人健康管理局启动ADT的前列腺腺癌患者,按ADT后6-9个月绝对PSA分为低(≤0.2 ng/ml)、中(>0.2至4 ng/ml)、高(>4 ng/ml)三组,发现PSA越高总体生存越差、前列腺癌特异性死亡风险越高,绝对PSA可预测总体死亡与PCSM。

要点

  • ADT后6-9个月绝对PSA低、中、高三组2年生存率分别为93.9%、88.6%、63.6%。
  • 高PSA组与中PSA组PCSM风险分别约为PSA<0.2 ng/ml者的15倍与3倍。
  • 该绝对PSA指标可快速评估2期临床试验中新干预的疗效。

核心结论

  • 激素敏感性前列腺癌患者ADT后6-9个月的绝对PSA是总体死亡与前列腺癌特异性死亡的预测因素。

研究设计与样本

  • 回顾性综述,纳入在退伍军人健康管理局接受诊疗、因前列腺腺癌启动ADT的男性患者9170例。

主要发现

  • ADT诱导后低、中、高PSA组分别有3508例、3419例、2243例。
  • 低、中、高PSA组2年与5年生存率分别为93.9%与85.2%、88.6%与71.2%、63.6%与38.6%(p<0.0001)。
  • 高PSA组与中PSA组PCSM风险分别约为PSA<0.2 ng/ml者的15倍与3倍(p<0.0001)。

关键数值与推荐

  • 绝对PSA分组采用西南肿瘤协作组9346试验所述标准:低≤0.2 ng/ml、中>0.2至4 ng/ml、高>4 ng/ml。
  • 主要终点为全因死亡与前列腺癌特异性死亡。
  • 采用Kaplan-Meier生存曲线与log-rank检验,并用校正协变量及逆倾向评分权重的Cox回归分析PSA分组与PCSM及全因死亡的关联。

临床怎么用

  • 作者认为该绝对PSA指标可快速评估2期临床试验中新干预的疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to determine if absolute prostate specific antigen (PSA) value after 6 months of androgen deprivation therapy (ADT) is predictive of subsequent survival in patients with prostate adenocarcinoma. MATERIALS AND METHODS: We performed a retrospective review of men receiving care within the Veterans Health Administration who initiated ADT for prostate adenocarcinoma. We used low- (≤0.2 ng/ml), intermediate- (>0.2 to 4 ng/ml) and high-risk (>4 ng/ml) absolute PSA values after 6-9 months of ADT, previously described in Southwest Oncology Group trial 9346. The primary endpoints were all-cause mortality and prostate cancer-specific mortality (PCSM). Kaplan-Meier survival curves for each PSA category were estimated and log-rank test was conducted. We employed Cox regression analysis adjusted for covariates and inverse propensity score weights associated with PSA categories to estimate the PSA category association with PCSM and all-cause mortality. RESULTS: We identified 9,170 patients in our cohort. Following ADT induction, 3,508 patients had low, 3,419 had intermediate and 2,243 had high PSA values. Two- and 5-year survival rates for low, intermediate and high PSA groups were 93.9% and 85.2% vs 88.6% and 71.2% vs 63.6% and 38.6%, respectively (p <0.0001). Patients in the high and intermediate PSA categories had a 15-fold and 3-fold higher risk of PCSM compared to those with PSA <0.2 ng/ml (p <0.0001). CONCLUSIONS: Absolute PSA in hormone-sensitive prostate cancer after 6-9 months of ADT is a predictor of overall mortality and PCSM. This measure can rapidly assess the efficacy of new interventions in phase 2 clinical trials.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Dursun F, Wang CP, MacCarthy D, et al. Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer. J Urol. 2022. PMID: 35343252. doi:10.1097/JU.0000000000002676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。